214 related articles for article (PubMed ID: 20205605)
1. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility.
Tran PH; Tran TT; Lee KH; Kim DJ; Lee BJ
Expert Opin Drug Deliv; 2010 May; 7(5):647-61. PubMed ID: 20205605
[TBL] [Abstract][Full Text] [Related]
2. pH modulation: a mechanism to obtain pH-independent drug release.
Bassi P; Kaur G
Expert Opin Drug Deliv; 2010 Jul; 7(7):845-57. PubMed ID: 20509776
[TBL] [Abstract][Full Text] [Related]
3. The roles of acidifiers in solid dispersions and physical mixtures.
Tran TT; Tran PH; Choi HG; Han HK; Lee BJ
Int J Pharm; 2010 Jan; 384(1-2):60-6. PubMed ID: 19782736
[TBL] [Abstract][Full Text] [Related]
4. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations.
Al-Hamidi H; Edwards AA; Mohammad MA; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Mar; 76(1):170-8. PubMed ID: 19945828
[TBL] [Abstract][Full Text] [Related]
5. Microenvironmental pH modulation in solid dosage forms.
Badawy SI; Hussain MA
J Pharm Sci; 2007 May; 96(5):948-59. PubMed ID: 17455349
[TBL] [Abstract][Full Text] [Related]
6. Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug.
Tran TT; Tran PH; Lee BJ
Eur J Pharm Biopharm; 2009 May; 72(1):83-90. PubMed ID: 19141319
[TBL] [Abstract][Full Text] [Related]
7. A novel pH-dependent gradient-release delivery system for nitrendipine II. Investigations of the factors affecting the release behaviors of the system.
Yang M; Cui F; You B; Wang L; Yue P; Kawashima Y
Int J Pharm; 2004 Nov; 286(1-2):99-109. PubMed ID: 15501006
[TBL] [Abstract][Full Text] [Related]
8. Design of a drug delivery system with bimodal pH dependent release of a poorly soluble drug.
Kovacic B; Vrecer F; Planinsek O
Pharmazie; 2011 Jun; 66(6):465-6. PubMed ID: 21699090
[TBL] [Abstract][Full Text] [Related]
9. Salt formation to improve drug solubility.
Serajuddin AT
Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
[TBL] [Abstract][Full Text] [Related]
10. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
11. Microenvironmental pH and microviscosity inside pH-controlled matrix tablets: an EPR imaging study.
Siepe S; Herrmann W; Borchert HH; Lueckel B; Kramer A; Ries A; Gurny R
J Control Release; 2006 May; 112(1):72-8. PubMed ID: 16476499
[TBL] [Abstract][Full Text] [Related]
12. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.
Riis T; Bauer-Brandl A; Wagner T; Kranz H
Eur J Pharm Biopharm; 2007 Jan; 65(1):78-84. PubMed ID: 16919924
[TBL] [Abstract][Full Text] [Related]
13. Dissolution behaviour of nalidixic acid solid dispersions using water soluble dispersion carriers.
Mallick S; Sahu A; Pal K
Acta Pol Pharm; 2004; 61(1):21-30. PubMed ID: 15259854
[TBL] [Abstract][Full Text] [Related]
14. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug.
Kranz H; Guthmann C; Wagner T; Lipp R; Reinhard J
Eur J Pharm Sci; 2005 Sep; 26(1):47-53. PubMed ID: 15953712
[TBL] [Abstract][Full Text] [Related]
15. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine.
Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ohike A; Ibuki R; Higaki K; Kimura T
J Control Release; 2005 Nov; 108(2-3):386-95. PubMed ID: 16253377
[TBL] [Abstract][Full Text] [Related]
16. Strategies for the design of hydrophilic matrix tablets with controlled microenvironmental pH.
Siepe S; Lueckel B; Kramer A; Ries A; Gurny R
Int J Pharm; 2006 Jun; 316(1-2):14-20. PubMed ID: 16551495
[TBL] [Abstract][Full Text] [Related]
17. Cyclodextrins as pharmaceutical solubilizers.
Brewster ME; Loftsson T
Adv Drug Deliv Rev; 2007 Jul; 59(7):645-66. PubMed ID: 17601630
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of solubility and dissolution of coenzyme Q10 using solid dispersion formulation.
Nepal PR; Han HK; Choi HK
Int J Pharm; 2010 Jan; 383(1-2):147-53. PubMed ID: 19781608
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
Wang XQ; Zhang Q
Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
[TBL] [Abstract][Full Text] [Related]
20. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
